- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04282811
Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy
January 3, 2022 updated by: Gruppo Italiano Malattie EMatologiche dell'Adulto
An Observational Study to Evaluate the Clinical and Biologic Features and Outcome of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated With Venetoclax-based Regimens Outside Clinical Trials in Italy
Observational study aimed at describing the characteristics and outcome of CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time ranging from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of venetoclax.
The study includes two different groups: a retrospective group (all patients who have received at least one dose of venetoclax before enrolment) and a prospective group (patients receiving treatment with venetoclax after enrolment).
All patients in both groups will be observed for up to 48 months from the treatment start.
In the prospective cohort only, QoL will be assessed at the time of study entry (i.e.
baseline) and thereafter at 3, 6, 9, 12, 18 24, 30, 36, 42 and 48 months of follow-up and at treatment discontinuation (due to any cause).
Study Type
Observational
Enrollment (Anticipated)
157
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alessandria, Italy
- Recruiting
- Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia
-
Contact:
- Daniela S Pietrasanta
- Email: dpietrasanta@ospedale.al.it
-
Bari, Italy
- Recruiting
- Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
-
Contact:
- Francesco C Albano
- Email: francesco.albano@uniba.it
-
Cagliari, Italy
- Recruiting
- Ao Brotzu, Presidio Ospedaliero A. Businco - Cagliari - Sc Ematologia E Ctmo
-
Contact:
- Roberta Murru
- Email: roberta.murru@tiscali.it
-
Catania, Italy
- Recruiting
- Ctc U.O Di Ematologia Con Trapianto Di Midollo Osseo - Catania
-
Contact:
- Annalisa Chiarenza
- Email: annalisa.chiarenza@gmail.com
-
Catanzaro, Italy
- Recruiting
- Ao Di Catanzaro "Pugliese-Ciaccio", Presidio Ospedaliero "Ciaccio - de Lellis" - Ematologia
-
Contact:
- Monica Stefano
- Email: smolica@libero.it
-
Cosenza, Italy
- Recruiting
- Ao Di Cosenza, Presidio Ospedaliero Annunziata - Uoc Ematologia
-
Contact:
- Massimo Gentile
- Email: massimogentile@virgilio.it
-
Firenze, Italy
- Recruiting
- Aou Careggi - Firenze - Sod Ematologia
-
Contact:
- Sanna Alessandro
-
Messina, Italy
- Recruiting
- Ao Ospedali Riuniti "Papardo Piemonte" - Po Papardo - Messina - Sc Ematologia
-
Milano, Italy
- Recruiting
- Irccs Ospedale S. Raffaele - Milano - Unità Neoplasie Linfocitarie B
-
Contact:
- Lydia Scarfò
-
Milano, Italy
- Recruiting
- Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia
-
Contact:
- Alessandra Tedeschi
-
Milano, Italy
- Recruiting
- Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora
-
Contact:
- Gianluigi P Reda
- Email: gianluigi.reda@policlinico.mi.it
-
Modena, Italy
- Recruiting
- Aou Di Modena - Sc Ematologia
-
Contact:
- Roberto Marasca
-
Novara, Italy
- Recruiting
- Aou Maggiore Della Carita' Di Novara - Scdu Ematologia
-
Palermo, Italy
- Recruiting
- Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo
-
Contact:
- Caterina Patti
- Email: k.patti@ospedaliriunitipalermo.it
-
Perugia, Italy
- Recruiting
- Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo
-
Contact:
- Paolo Sportoletti
- Email: paolo.sportoletti@unipg.it
-
Pisa, Italy
- Recruiting
- Aou Pisana - Uo Ematologia Universitaria
-
Contact:
- Sara Galimberti
- Email: sara.galimberti@med.unipi.it
-
Ravenna, Italy
- Recruiting
- Ausl Della Romagna, Ospedale "Santa Maria Delle Croci" - Ravenna - Ematologia
-
Contact:
- Monica Tani
- Email: monica.tani@ausl.ra.it
-
Reggio Calabria, Italy
- Recruiting
- Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Po E. Morelli - Reggio Calabria - Uoc Ematologia
-
Contact:
- Caterina Stelitano
- Email: caterinastelitano27@gmail.com
-
Reggio Emilia, Italy
- Recruiting
- Ausl Di Reggio Emilia - Arcispedale Santa Maria Nuova, Irccs - Sc Ematologia
-
Contact:
- Angela Ferrari
- Email: angela.ferrari@ausl.re.it
-
Roma, Italy
- Recruiting
- Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
-
Contact:
- Francesca R Mauro
- Email: mauro@bce.uniroma1.it
-
Roma, Italy
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica
-
Contact:
- Luca Laurenti
- Email: luca.laurenti@Unicatt.it
-
Terni, Italy
- Recruiting
- Ao S. Maria - Terni - Sc Onco Ematologia
-
Torino, Italy
- Recruiting
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia - Università Degli Studi Di Torino
-
Torino, Italy
- Recruiting
- Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2
-
Varese, Italy
- Recruiting
- Asst Dei Sette Laghi, Ospedale Di Circolo E Fondazione Macchi - Uoc Ematologia
-
Contact:
- Andrea Ferrario
- Email: andrea.ferrario@asst-settelaghi.it
-
Verona, Italy
- Recruiting
- Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
-
Contact:
- Francesca Maria Quaglia
- Email: francescamaria.quaglia@gmail.com
-
-
Ferrara
-
Cona, Ferrara, Italy
- Recruiting
- Aou Arcispedale Sant'Anna - Cona (Fe) - Uoc Ematologia E Fisiopatologia Della Coagulazione
-
Contact:
- GianMatteo Rigolin
- Email: rglgmt@unife.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
CLL patients who started treatment with venetoclax-based regimens according to the local label outside clinical trials in Italy in a period of time ranging from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021.
Description
Inclusion Criteria
- Patients with R/R CLL fulfilling the eligibility criteria required by the Venetoclax Named Patient Program who have received at least 1 dose of venetoclax.
- Patients with R/R CLL who have received at least 1 dose of venetoclax or are scheduled to start treatment with venetoclax according to the Post-marketing Use before October 31st, 2021.
- Signed informed consent document (if feasible) according to ICH/EU/GCP and national local laws indicating that the patients understand the purpose of the study and they agree to give complete access to their medical records.
Exclusion Criteria:
None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cohort group
Patients who have received at least one dose of venetoclax
|
Patients treated with venetoclax-based regimens outside clinical trials in Italy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimation of the PFS in relapsed/refractory (R/R) patients with CLL treated with venetoclax-based regimens according to the local label outside clinical trials in Italy.
Time Frame: 15 months
|
Estimation of the PFS at 15 months from the start of venetoclax treatment in patients with R/R CLL who started treatment with venetoclax-based regimens according to the local label from the start of the Venetoclax Named Patient Program (March 2016) until October 31st, 2021
|
15 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 24, 2020
Primary Completion (ANTICIPATED)
January 31, 2023
Study Completion (ANTICIPATED)
October 31, 2025
Study Registration Dates
First Submitted
February 21, 2020
First Submitted That Met QC Criteria
February 21, 2020
First Posted (ACTUAL)
February 25, 2020
Study Record Updates
Last Update Posted (ACTUAL)
January 4, 2022
Last Update Submitted That Met QC Criteria
January 3, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLL1920
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
BioSight Ltd.Recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States